PITTSBURGH, Jan. 6, 2025 /PRNewswire/ - MolecuLight Inc., a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load in wounds, today announced it has secured a $27.5 million investment from Hayfin Capital Management LLP ("Hayfin"). This significant investment will accelerate MolecuLight's continued growth in the United States, Canada, and Europe across hospital in-patient and out-patient clinics, independent wound care clinics, podiatrists, mobile care, skilled nursing facilities, and long-term care centers.

MolecuLight's innovative fluorescence imaging devices are transforming the way healthcare providers detect and treat infections. By providing real-time visualization of harmful bacteria in all wound types, these devices empower clinicians to make informed decisions and improve patient outcomes while reducing cost-to-care^1,2. This includes shortened healing times, reduced use of unnecessary antibiotics, complication avoidance, and minimized failure of skin substitutes products^1,3,4..

"We are thrilled to partner with Hayfin, a leading global alternative investment manager which has extensive investment experience in companies focused on wound care," said Anil Amlani, CEO of MolecuLight. "This investment will enable us to accelerate our goal of improving how wounds are treated worldwide. We will further expand our footprint to reach more healthcare providers and patients while continuing to develop additional cutting-edge features including thermal imaging, 3D wound visualization, and other unique feature sets that will be announced over the next 6 months."

"We are excited to partner with MolecuLight and support their continued growth. MolecuLight's imaging device is a best-in-class product with broad market traction and a strong R&D and Product Development pipeline. These attributes importantly create a unique solution for an unmet need in the wound care space that is transformative for patients, providers, and the healthcare system as a whole and make it an ideal fit for our investing strategy. Our capital support will enable MolecuLight to accelerate its growth and impact." said Andrew Merrill, Managing Director, Hayfin.

Tungsten Advisors acted as the sole placement agent for the offering.

‍